LAB Q4 2023 Earnings — Standard BioTools Inc. Revenue & Financial Results | Market Cap Arena

LABStandard BioTools Inc.

$388M

Q4 2023 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$28M+4.3% YoY

Gross Profit

$13M47.4% margin

Operating Income

-$21M-75.9% margin

Net Income

-$20M-70.2% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

+11.1%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$323M

Total Liabilities

$160M

Stockholders' Equity

$163M

Cash & Equivalents

$52M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$28M	$27M	+4.3%
Gross Profit	$13M	$11M	+19.6%
Operating Income	-$21M	-$21M	-1.3%
Net Income	-$20M	-$21M	+5.1%

Revenue Segments

Product And Service

$52M36%

Product

$39M27%

Consumables

$22M15%

Instruments

$17M12%

Service

$14M9%

Product and Service, Other

$892,0001%

Geographic Segments

Americas

$13M47%

EMEA

$9M31%

Asia Pacific

$6M22%